药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

Xolair被认为是治疗食物过敏的“突破性”疗法

2018-08-15 MedSci MedSci原创

Xolair食物过敏
关注

罗氏(Roche) /诺华(Novartis)的Xolair在美国被授予突破性地位，用于治疗意外接触食物过敏原后出现的严重过敏反应。Xolair (omalizumab)是一种针对免疫球蛋白E的单克隆抗体，已在美国获准用于治疗哮喘和慢性特发性荨麻疹(无已知病因的慢性荨麻疹)。突破性治疗指定食物过敏 - 影响美国高达8％的儿童和4％的成年人--来自七项临床研究的数据，这些研究评估了该药物对一系列食物



罗氏(Roche) /诺华(Novartis)的Xolair在美国被授予突破性地位，用于治疗意外接触食物过敏原后出现的严重过敏反应。

Xolair (omalizumab)是一种针对免疫球蛋白E的单克隆抗体，已在美国获准用于治疗哮喘和慢性特发性荨麻疹(无已知病因的慢性荨麻疹)。

突破性治疗指定食物过敏 - 影响美国高达8％的儿童和4％的成年人--来自七项临床研究的数据，这些研究评估了该药物对一系列食物过敏原的有效性和安全性，包括花生，牛奶，鸡蛋等。
"食物过敏会对儿童和成人的生活产生重大影响，并且他们正在成为一个日益增长的公共卫生问题，目前尚无FDA批准的治疗方法，"首席医疗官兼全球产品开发负责人Sandra Horning说。

"我们致力于帮助解决这一未满足的医疗需求，并期待与该领域的领导者合作，进一步开发Xolair作为一种潜在的药物，帮助患有这种可能危及生命的病人。"


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720675, encodeId=cf201e206756c, content=<a href='/topic/show?id=3a3318846c9' target=_blank style='color:#2F92EE;'>#Xolair#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18846, encryptionId=3a3318846c9, topicName=Xolair)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a532912203, createdName=lancelotzzl, createdTime=Mon May 27 16:37:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416828, encodeId=5245141682809, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Fri Aug 17 04:37:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338792, encodeId=831c338e9201, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 15 17:09:47 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338781, encodeId=edb8338e81d3, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Aug 15 13:59:11 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2019-05-27 lancelotzzl

    #Xolair#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1720675, encodeId=cf201e206756c, content=<a href='/topic/show?id=3a3318846c9' target=_blank style='color:#2F92EE;'>#Xolair#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18846, encryptionId=3a3318846c9, topicName=Xolair)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a532912203, createdName=lancelotzzl, createdTime=Mon May 27 16:37:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416828, encodeId=5245141682809, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Fri Aug 17 04:37:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338792, encodeId=831c338e9201, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 15 17:09:47 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338781, encodeId=edb8338e81d3, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Aug 15 13:59:11 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-17 yhy100201

    #食物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1720675, encodeId=cf201e206756c, content=<a href='/topic/show?id=3a3318846c9' target=_blank style='color:#2F92EE;'>#Xolair#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18846, encryptionId=3a3318846c9, topicName=Xolair)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a532912203, createdName=lancelotzzl, createdTime=Mon May 27 16:37:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416828, encodeId=5245141682809, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Fri Aug 17 04:37:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338792, encodeId=831c338e9201, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 15 17:09:47 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338781, encodeId=edb8338e81d3, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Aug 15 13:59:11 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-15 wxl882001

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1720675, encodeId=cf201e206756c, content=<a href='/topic/show?id=3a3318846c9' target=_blank style='color:#2F92EE;'>#Xolair#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18846, encryptionId=3a3318846c9, topicName=Xolair)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99a532912203, createdName=lancelotzzl, createdTime=Mon May 27 16:37:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416828, encodeId=5245141682809, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Fri Aug 17 04:37:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338792, encodeId=831c338e9201, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 15 17:09:47 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338781, encodeId=edb8338e81d3, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Aug 15 13:59:11 CST 2018, time=2018-08-15, status=1, ipAttribution=)]
    2018-08-15 1ddf0692m34(暂无匿称)

    学习了，长知识

    0

相关资讯

FDA授予IgE单抗Xolair突破性疗法认定，治疗食物过敏

罗氏和诺华公司的过敏药物Xolair（omalizumab）获得FDA突破性认定，用于治疗新的适应症--食品过敏。